Latest Information Update: 24 Aug 1999
At a glance
- Originator GlaxoSmithKline
- Class Antimigraines
- Mechanism of Action Serotonin 1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 24 Aug 1999 Discontinued-I for Migraine in United Kingdom (Unknown route)
- 03 Feb 1997 No-Development-Reported for Migraine in United Kingdom (Unknown route)